Evaluation of Cancer Specific Mortality with Surgery versus Radiation as Primary Therapy for Localized High Grade Prostate Cancer in Men Younger Than 60 Years

Huang, Hubert; Muscatelli, Stefano; Naslund, Michael J.; Badiyan, Shahed N.; Kaiser, Adeel; Siddiqui, Mohummad Minhaj

doi:10.1016/j.juro.2018.07.049

Cited by 18 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prostate cancer (PCa) continues to plague male health around the world, representing the most common malignant tumor among male patients, accompanied by the second highest mortality rate in male patients with malignant tumors 1–3. Studies have revealed that, in 2016, 180,890 male patients in the USA were diagnosed with PCa, and another 85,920 patients succumbed to PCa 4.…”

Section: Introductionmentioning

confidence: 99%

<p>Overexpression of shugoshin1 predicts a poor prognosis for prostate cancer and promotes metastasis by affecting epithelial–mesenchymal transition</p>

Mu¹,

Fan²,

Liu³

et al. 2019

OTT

View full text Add to dashboard Cite

The aim of the study was to investigate the role of shugoshinl (SGO1) in human prostate cancer (PCa). Materials and methods: Quantitative real-time PCR (qRT-PCR) was used to determine the expression of SGO1 in PCa tissues and cell lines. The correlation between SGO1 expression and clinicopathological characteristics of PCa patients was analyzed using Kaplan-Meier analysis. SGO1 siRNA was successfully constructed and transfected into PCa cell lines (LNCaP and PC3). The knockdown efficacy was assessed by qRT-PCR. MTT assay and Transwell assay were conducted to observe the effect of SGO1 on the proliferation and invasion of PCa cell lines. Results: SGO1-expression levels were found to be higher in the PCa tissues and cell lines. Correlation was identified between the expression of SGO1 and preoperative prostate-specific antigen (P=0.017), lymph-node metastasis (P=0.044), and Gleason score (P=0.041). Patients with higher SGO1 expression displayed more advanced clinicopathological characteristics in addition to a shorter biochemical recurrence-free survival time. Additionally, SGO1 knockdown resulted in the inhibition of PCa cell proliferation, migration, and invasion. Conclusion: Taken together, the findings of the current study present evidence suggesting that SGO1 could inhibit the growth and invasion of PCa cells, highlighting its potential as a novel therapeutic target for the treatment of PCa.

show abstract

Section: Introductionmentioning

confidence: 99%

<p>Overexpression of shugoshin1 predicts a poor prognosis for prostate cancer and promotes metastasis by affecting epithelial–mesenchymal transition</p>

Mu¹,

Fan²,

Liu³

et al. 2019

OTT

View full text Add to dashboard Cite

show abstract

“…The factors of GS, PSA or T stage are the widely accepted risk-grading standards in non-metastatic prostate cancer and have great impacts on the treatment decisions 15 . High-grade PCa has a great impact on the prognosis of patients and has always been one of the focuses in PCa researches 16 , 17 . In general, PCa with higher PSA levels or T stages is more aggressive and associated with poorer prognosis for the patients.…”

Section: Discussionmentioning

confidence: 99%

Survival outcomes of low prostate-specific antigen levels and T stages in patients with high-grade prostate cancer: a population-matched study

et al. 2020

View full text Add to dashboard Cite

Objective: To evaluate the prostate cancer-specific survival (PCSS) of low T stages or low prostatespecific antigens (PSA) levels in men with high-grade prostate cancer. Materials and Methods: Patients with non-metastatic prostate cancer (T1-4N0M0) and Gleason score 8-10 in the Surveillance, Epidemiology, and End Results database from 2004-2010 were identified. These men were stratified by T stages (T1, T2, T3a, T3b-4) and PSA levels (<4.0 ng/ml, 4.0-10.0 ng/ml, 10.1-20.0 ng/ml, >20.0 ng/ml). Propensity-score matching (PSM) was conducted to balance the covariates. Kaplan-Meier analysis and multivariable Cox regressions were performed to analyze the PCSS in different T stage or PSA levels groups. Results: A total of 33231 patients aging 69(62~76) years were identified. The overall cohort results showed that the PCSS of T1 group was significantly worse than that of T2 and T3a groups [T2 HR: 0.62(0.57~0.67); T3 HR: 0.70(0.63~0.77)]. There were no significant difference between T2 and T3a groups [T2 HR: 0.98 (0.91~1.05)]. The PSA <4.0 ng/ml group had significantly worse PCSS than PSA 4.

show abstract

“…A randomized controlled trial is the ideal approach for comparing competing treatment modalities (19). However, most of the previously reported literatures comparing the e cacy of LDR and RP are retrospective studies (14,20). Compared with candidates for RP, patients who are offered LDR generally tend to be older and have higher comorbidity scores, therefore, a random trial is impractical (17,18).…”

Section: Discussionmentioning

confidence: 99%

Treatment outcomes of 125I low-dose-rate brachytherapy vs radical prostatectomy for patients with intermediate-risk prostate cancer

Zhou¹,

Liang²,

Zhou³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Radical prostatectomy (RP) and low-dose-rate brachytherapy (LDR) are two widely used treatment options for patients with intermediate-risk prostate cancer (IRPC). However, which one is better remains controversial. Therefore, the purpose of this study was to compare the efficacy of RP vs LDR for patients with IRPC. Methods: A retrospective analysis was performed on 361 IRPC patients who underwent treatment from January 2010 and August 2017. 160 underwent RP and 201 underwent LDR using Iodine-125. Biochemical failure for RP was defined as prostate-specific antigen (PSA) levels > 0.2 ng/ml, and for LDR as nadir PSA level + 2 ng/ml. The log-rank test compared biochemical relapse-free survival (bRFS) between the two modalities, and Cox regression identified factors associated with bRFS. Results: Median follow-up was 54 months for RP and 69 months for LDR. The 5-and 8-year bRFS rates were 70.2% and 63.1% in the RP group, and 83.2% and 68.9% in the LDR group, respectively, P=0.003. There were no significant differences in terms of clinical relapse-free survival (cRFS), cancer-specific survival (CSS) or overall survival (OS) between the two groups. Conclusion: LDR is a reasonable treatment option for IRPC patients, yielding improved bRFS and equivalent rates of cRFS, CSS and OS compared with RP.

show abstract

Evaluation of Cancer Specific Mortality with Surgery versus Radiation as Primary Therapy for Localized High Grade Prostate Cancer in Men Younger Than 60 Years

Abstract: Our data show significant survival differences in young men treated initially with surgery versus external beam radiation therapy for high-grade prostate cancer. Future prospective randomized trials are needed to confirm long-term outcomes of these treatment approaches.

Cited by 18 publications

References 0 publications

<p>Overexpression of shugoshin1 predicts a poor prognosis for prostate cancer and promotes metastasis by affecting epithelial–mesenchymal transition</p>

<p>Overexpression of shugoshin1 predicts a poor prognosis for prostate cancer and promotes metastasis by affecting epithelial–mesenchymal transition</p>

Survival outcomes of low prostate-specific antigen levels and T stages in patients with high-grade prostate cancer: a population-matched study

Treatment outcomes of 125I low-dose-rate brachytherapy vs radical prostatectomy for patients with intermediate-risk prostate cancer

Contact Info

Product

Resources

About

Evaluation of Cancer Specific Mortality with Surgery versus Radiation as Primary Therapy for Localized High Grade Prostate Cancer in Men Younger Than 60 Years

Abstract: Our data show significant survival differences in young men treated initially with surgery versus external beam radiation therapy for high-grade prostate cancer. Future prospective randomized trials are needed to confirm long-term outcomes of these treatment approaches.

Cited by 18 publications

References 0 publications

<p>Overexpression of shugoshin1 predicts a poor prognosis for prostate cancer and promotes metastasis by affecting epithelial&ndash;mesenchymal transition</p>

<p>Overexpression of shugoshin1 predicts a poor prognosis for prostate cancer and promotes metastasis by affecting epithelial&ndash;mesenchymal transition</p>

Survival outcomes of low prostate-specific antigen levels and T stages in patients with high-grade prostate cancer: a population-matched study

Treatment outcomes of 125I low-dose-rate brachytherapy vs radical prostatectomy for patients with intermediate-risk prostate cancer

Contact Info

Product

Resources

About

<p>Overexpression of shugoshin1 predicts a poor prognosis for prostate cancer and promotes metastasis by affecting epithelial–mesenchymal transition</p>

<p>Overexpression of shugoshin1 predicts a poor prognosis for prostate cancer and promotes metastasis by affecting epithelial–mesenchymal transition</p>